GERMANY – mbiomics, a Munich, Germany-based microbiome biotech company developing microbiome-based therapeutics, raised €13M in Series A funding.
The round was led by MIG, with participation from High-Tech Gründerfonds, Bayern Kapital and private seed investors.The company intends to use the funds to embark on strategic partnerships, expand its Munich laboratory facilities and R&D teams in Germany, and potentially increase US activities. Founded in 2020 and led by CEO Dr. Laura Figulla, mbiomics is a biotech company with a focus on developing the first generation of effective live bacterial therapeutics (LBT). It uses its proprietary high-resolution profiling platform and computational techniques to generate precision data on microbiota modulation, selecting better informed consortia, improving patient stratification and patient monitoring for clinical trials.23/03/2023
